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Abstract
Constitutively activated signal transducers and acti-
vators of transcription (STAT) are reported to cause
uncontrolled transmission of growth signals. In this
study, we analyzed the roles of an inhibitor of STAT,
protein inhibitor of activated STAT (PIAS) 3, in the
development of lung cancer. Treatment with an in-
hibitor of phosphatidylinositol 3-kinase, LY294002,
retarded the growth of human lung cancer cells and
rendered them more sensitive to chemotherapeutic
agents. However, the inhibition of JAK/STAT by AG490
significantly suppressed cell growth but did not in-
crease drug sensitivity at all. Overexpression of PIAS3
not only significantly inhibited cell growth but also
rendered cancer cells up to 12.0-fold more sensitive to
the above drugs, which was associated with the sup-
pression of Akt phosphorylation. Inhibition of PIAS3
with small interfering RNA, nevertheless, led cancer
cells to accelerate cell proliferation, deteriorate chemo-
sensitivity, and augment Akt phosphorylation. Al-
though the overexpression of suppressors of cytokine
signaling 3 in cancer cells also inhibited cell growth and
STAT3 phosphorylation, it neither increased sensitivity
to chemotherapeutic drugs nor affected the phosphor-
ylation of Akt. These results indicate that PIAS3 may
be an attractive candidate for targeting the JAK/STAT
and PI3-K/Akt signaling pathways in cancer treatment.
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Introduction
Lung cancer is the leading cause of death in adult men in
Europe, the United States, and Japan. In 2004, approxi-
mately 160,440 Americans died of lung cancer from among
563,700 cancer deaths [1]. About 75% of lung cancers are
locally advanced or have metastases. Clinical trials have
demonstrated median survival times between 35 and
40 weeks, and 1-year survival rates of 20% to 25% [2–4].
Tyrosine kinase (TK) growth factor receptors on the cell
surface are good targets in cancer therapy because signals
from these receptors promote cell growth and survival. A TK
inhibitor, erlotinib, was shown to be superior to placebo in terms
of survival and tumor response rate in epidermal growth factor
receptor (EGFR)–positive patients with locally advanced or
metastatic non–small cell lung cancer (NSCLC) [5]. Specific
mutations in the EGFR gene have been reported to correlate
with clinical responsiveness to another EGFR TK inhibitor,
gefitinib [6]. The binding of TK growth factors or cytokines to
their corresponding receptors leads to conformational changes
of the receptors that initiate the activation of JAK. Then, JAK ac-
tivates signal transducers and activators of transcription (STAT)
factors to dimerize and translocate into the nucleus to initiate
the transactivation of target genes. This pathway is crucial
to hematopoiesis, immune response, and oncogenesis [7]. In
many cancers, STAT are constitutively activated to upregulate
genes encoding apoptosis inhibitors and cell cycle regulators
such as Bcl-xL, Mcl-1, cyclins D1/D2, and c-Myc [7–9].
Dysfunction of the regulatory system for the JAK/STAT
pathway has been demonstrated in the development of cancer.
Three families of proteins, the protein inhibitors of activated
STAT (PIAS) [10], the suppressors of cytokine signaling
(SOCS) [11–13], and the Src homology 2 containing phospha-
tase (SHP) [14], participate in the negative regulation of this
signal transduction pathway [15]. SOCS proteins become in-
ducible inhibitors of this signaling pathway by competing with
STAT for phosphorylated binding sites on receptors or by tar-
geting bound signaling proteins for proteasomal degradation.
SHP and PIAS family members are constitutively expressed
and can attenuate signal transduction [16]. Recently, He et al.
reported that the activity of SOCS3 was silenced due to hyper-
methylation in its promoter region in seven of eight human lung
cancer samples tested. They restored SOCS3 expression in
those cancer cells and thereby successfully suppressed tumor-
igenicity [17]. Wu et al. [18] reported that the expression of
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SHP1 proteins or mRNAwas dramatically decreased in most
leukemia and lymphoma cell lines. Overexpression of SHP1
suppressed the growth of cancer cells. Because STAT3 is
frequently activated in a wide variety of human malignancies
[19], PIAS3, a specific regulator of STAT3, is possibly an ideal
candidate for controlling cancer. However, only a small
number of reports on the involvement of PIAS3 in cancer
development are available so far. Zhang et al. [20] reported
that they could not detect PIAS3 mRNA in most samples of
lymphoma cells, and they speculated that loss of PIAS3
expression is partly responsible for the activation of STAT3.
Wible et al. [21] reported that ectopic expression of PIAS3
suppressed the survival of prostate cancer cells by inducing
the apoptosis of cancer cells.
We demonstrated here that overexpression of PIAS3 in
lung cancer cells contributed to growth suppression and
restored the drug sensitivity of the cells. The anticancer
effects of PIAS3 were associated with the suppression of
antiapoptotic molecules, including Akt and Bcl-xL. However,
overexpression of SOCS3 induced growth suppression
but affected neither the drug sensitivity nor the phosphory-
lation of Akt. PIAS3 may be a good target for interference
with cell signaling for potential therapeutic intervention in
lung cancer.
Materials and Methods
Materials
The following materials were used: anti–phospho-STAT3,
anti –phospho-Erk1/2, and anti–phospho-Akt antibodies
(Cell Signaling Technology, Beverly, MA); antibody to PIAS3
(Santa Cruz Biotechnology, Santa Cruz, CA); anti–b-actin
antibody (Sigma, St. Louis, MO); and AG490 and LY294002
(Calbiochem, San Diego, CA). Recombinant human inter-
leukin (IL) 6 protein was purchased from PeproTech EC
(London, UK). Carboplatin (CBDCA) was kindly provided
by Bristol-Myers Squibb Japan (Tokyo, Japan), and vinorel-
bine (VNR) was a gift from Kyowa Hakko Kogyo Co. Ltd.
(Tokyo, Japan).
Cell Lines
The human lung cancer cell lines A549, VMRC-LCD
(LCD), EBC1, and RERF-LCMS were obtained from the
Japanese Collection of Research Bioresources (Osaka,
Japan). These cells were cultured in RPMI 1640 supple-
mented with 10% fetal bovine serum (FBS) and penicillin/
streptomycin. The human PIAS3 cDNA cloned in a pCl-neo-
Myc expression vector (Promega, Palo Alto, CA) was kindly
provided by Dr. Tadashi Matsuda (Hokkaido University,
Sapporo, Japan). PIAS3-transfected cells were established
after stable transfection with the PIAS3 expression vector or
pSV2neo (mock) using Lipofectamine Plus (Invitrogen,
Tokyo, Japan). These cells were cultured in RPMI supple-
mented with 10% FBS and 500 mg/ml Geneticin (Gibco,
Grand Island, NY), and were maintained under standard cell
culture conditions at 37jC and 5% CO2 in a humidified
environment. We confirmed an ectopic PIAS3 gene expres-
sion in established clones by immunoblotting using an Myc
tag. Representative clones expressing high levels of PIAS3
were used in the following experiments.
Adenoviral Vectors
Recombinant replication-defective adenoviral vectors
were constructed by the cosmid–adenoviral DNA terminal
protein complex method [22]. Adenoviral vectors AdCATK
and AdSOCS3 were designed to express the thymidine
kinase gene and the human SOCS3 gene, respectively,
under the control of the CAG promoter (a modified chicken
b-actin promoter with a cytomegalovirus immediate early
enhancer) [23]. Solutions of these adenoviral vectors were
prepared as described previously and stored at 80jC until
use [24]. After seeding 1  105 cells in a six-well plate and
culturing them in RPMI 1640 supplemented with 10%FBS for
24 hours, the infection of adenoviral vectors was performed
by distributing suspensions of AdSOCS3 or AdCATK onto
cells at a multiplicity of infection (MOI) of 20, followed by
incubation at 37jC for an additional 24 hours.
Cellular Proliferation Assay
Cell growth curves were determined by plating 1 
105 cells in a six-well plate and by culturing the cells in RPMI
1640 supplemented with 10% FBS for 24 hours. Then, after
the cells had been deprived of serum for 20 hours, 60 mM
AG490, 10 mMLY294002, or dimethyl sulfoxide (DMSO) alone
was added to the cells, followed by incubation at 37jC in
RPMI 1640 supplemented with 5% FBS. The cells were
stained with trypan blue and counted at indicated intervals.
In Vitro Sensitivity of Tumor Cells to
Chemotherapeutic Drugs
Five thousand A549, LCD, EBC1, and LCMS cells were
seeded in triplicate onto 96-well culture plates and were
cultured in RPMI 1640 supplemented with 10% FBS for
24 hours. After the cells had been deprived of serum for
20 hours, the medium was replaced with a medium contain-
ing 10% FBS with DMSO alone, 60 mM AG490 dissolved in
DMSO, or 10 mM LY294002 solubilized in DMSO. After a
24-hour incubation with these inhibitors, various concentra-
tions of CBDCA or VNR were added to the wells. After
cultivation for an additional 72 hours, the 3-[4,5-dimethyl-
thiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay
was carried out as described previously [25]. The 50%
growth-inhibitory concentration (IC50) of CBDCA and VNR
for each cell line was calculated using a curve-fitting pa-
rameter. The fold increase of drug sensitivity was calcu-
lated as the IC50 values of mock-transfected cells divided
by those of PIAS3-transfected or SOCS3-transfected cells,
and the findings were presented as mean ± SD from three
independent experiments.
Immunoblotting Analysis
After subconfluent tumor cells had been cultured in a
medium without serum for 20 hours, 100 ng/ml IL-6 was
added to each well. The cells were harvested at indicated
intervals and analyzed for the phosphorylation of Akt, STAT,
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and Erk1/2. For Bcl-xL, after subconfluent tumor cells had
been cultured in a medium without serum for 20 hours, an
indicated concentration of CBDCA was added to each well,
and the cells were harvested 24 hours later. Protein ex-
traction, immunoprecipitation, Western blot analysis, and
immunoblotting were performed as previously described [26].
Small Interfering RNA (siRNA) against PIAS3
We purchased an siRNA cocktail against human PIAS3
from B-Bridge International, Inc. (Sunnyvale, CA), which con-
tains three siRNA: first sequence (sense 5V-cuacaaaaacuca-
gagcaaTT-3V and antisense 5V-uugcucugaguuuuuguagTT-3V),
second sequence (sense 5V-cauccaagguuuagauuuaTT-3V and
antisense 5V-uaaaucuaaccuuggaugTT-3V), and third sequence
(sense 5V-caaacagacagguggaaaaTT-3V and antisense 5V-
uuuuccaccugucuguuugTT-3V). A negative control cocktail
was also purchased from B-Bridge International, Inc. (cat.
no. C6A-0126). Transfection of siRNA was performed accord-
ing to the manufacturer’s instruction. After a 48-hour incuba-
tion, cells were subjected to chemosensitivity tests and
immunoblotting analyses.
Statistical Analysis
Data are indicated as mean ± SD for the number of
experiments indicated. Fisher’s protected least significant
difference (PLSD) test was used for the statistical analysis
of cell numbers and IC50 under individual conditions. Differ-
ences were considered significant at P < .05.
Results
Inhibition of Phosphatidylinositol 3-Kinase (PI3-K)
by LY294002 Induced Growth Inhibition and Increased
the Cytotoxic Drug Sensitivity of Human Lung Cancer
Cells, Whereas Inhibition of JAK by AG490 Only
Suppressed Cell Growth
Lung cancer cells are relatively resistant to conventional
chemotherapeutic drugs but undergo extensive apoptosis
after treatment with pharmacological inhibitors of PI3-K/Akt
or JAK/STAT signaling [27]. To analyze if the growth rate
and drug sensitivity of human lung cancer A549 and LCD
cells are dependent on the activities of these signaling path-
ways, both cells were treated with the JAK inhibitor AG490
and the PI3-K inhibitor LY294002. Cells were grown in an
RPMI medium containing 5% FBS with 60 mM AG490, 10 mM
LY294002, or DMSO alone. The concentration of each agent
has been confirmed to suppress the expression of phosphor-
ylated (p)STATor pAkt, respectively (data not shown). Treat-
ment with AG490 or LY294002 significantly suppressed the
growth of both of these cell lines in comparison with the
respectiveDMSO-treated cells [Figure 1A, untreated A549 vs
A549 treated with AG490 (P = .0007 on day 6); Figure 1B,
untreated LCD versus LCD treatedwith AG490 (P = .0012; on
day 7); Figure 1C, untreated A549 cells versus A549 treated
with LY294002 (P = .0009 on day 5)].
Because both PI3-K/Akt and JAK/STAT signaling path-
ways have antiapoptotic activities and possibly havemediated
Figure 1. JAK inhibition by AG490 and PI3-K inhibition by LY294002 suppressed cell growth and increased the drug sensitivity of human lung cancer cells. Growth
curves of A549 (A) and LCD (B) cells treated with the JAK inhibitor AG490. Cells were grown in an RPMI medium containing 5% FBS with 60 M AG490 or DMSO
(untreated). (C) Growth curves of A549 cells treated with the PI-3K inhibitor LY294002. Cells were cultured in an RPMI medium containing 5% FBS with 10 M
LY294002 or DMSO (untreated). Viable cell numbers were counted using trypan blue dye exclusion at the indicated times after seeding. Each value is the average
(points) of triplicate dishes ± SD (bars). (D) LY294002 treatment increased the drug sensitivity of lung cancer cells. The fold increase in drug sensitivity was
calculated as the IC50 of DMSO-treated cells divided by those of LY294002-treated or AG490-treated cells. The values are expressed as mean ± SD from three
individual experiments. CBDCA, carboplatin; VNR, vinorelbine.
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resistance to a wide variety of chemotherapeutic agents in
lung cancer cells, we next studied whether treatment with
AG490 and LY294002 affected the sensitivity of lung cancer
cells to CBDCA and VNR, which are frequently used for lung
cancer treatment. The number of viable cells was determined
using the MTT assay and graphed as the percentage of
untreated cells at different doses of CBDCA and VNR in the
absence or in the presence of AG490 or LY294002. Drug
sensitivity was expressed as IC50 using a curve-fitting param-
eter. Fold increase in drug sensitivity was calculated as the
IC50 of DMSO-treated cells divided by those of LY294002-
treated or AG490-treated cells. Treatment with LY294002
rendered A549 cells 2.85-fold and 7.00-fold more sensitive
to CBDCA and VNR, respectively (Figure 1D, LY294002). In
contrast, AG490-treated A549 cells were still resistant to
both CBDCA and VNR (Figure 1D, AG490).
Establishment of PIAS3-Overexpressing Lung Cancer Cells
To analyze the effects of PIAS3 on cell growth and drug
sensitivity, we transfected A549, LCD, and EBC1 cells with a
plasmid vector encoding human PIAS3 and established
clones expressing high levels of PIAS3 by culturing them in
a medium containing Geneticin. We confirmed an ectopic
PIAS3 expression in the established clones of A549, LCD,
and EBC1 using anMyc tag (Figure 2A; indicated as PIAS3–
c-Myc fusion protein). Selected clones showed levels of
PIAS3 proteins higher than those of their parental cells, as
indicated by 68-kDa bands (Figure 2B; indicated as PIAS3).
We used PIAS3 clones in the following experiments and
showed the representative results of these clones.
We studied changes in the phosphorylation status of STAT
in PIAS-transfected cells. In mock-transfected A549 cells,
high levels of pSTATexpression appeared as early as 5 min-
utes after IL-6 stimulation and continued until at least 30 min-
utes after stimulation (Figure 2C, upper panel, A549/mock).
However, PIAS3-overexpressing A549 cells showed a de-
layed and attenuated phosphorylation of STAT3 (Figure 2C,
upper panel, A549/PIAS3). Overexpression of PIAS3 di-
minished the phosphorylation of STAT3 earlier in EBC1 cells
(Figure 2C, lower panel, EBC1/PIAS3). In LCD cells, the
intensity of pSTAT3 bands in PIAS3-overexpressing cells
was very similar to that in mock-transfected LCD cells
(Figure 2C, middle panel ).
Overexpression of PIAS3 Increased Drug Sensitivity
and Retarded the Growth of Human Lung Cancer
Cells, Whereas Overexpression of SOCS3 Only
Suppressed Cell Growth
We analyzed the effects of the JAK/STAT signaling path-
way inhibitory molecules PIAS3 and SOCS3 on the cell
growth and drug sensitivity of lung cancer cells. We trans-
duced SOCS3 using an adenoviral vector. The growth
curves of A549 cells were studied after the cells had been
transfected with PIAS3, alone or combined with SOCS3. The
growth rate of A549 cells was remarkably suppressed when
the cells were transfected with either PIAS3 or SOCS3
[Figure 3A, AdCATK versus PIAS3 AdCATK (P = .004 on
day 7); AdCATK versus AdSOCS3 (P = .0001 on day 7)]. The
magnitude of growth suppression was greater in SOCS3-
transfected cells than in PIAS3-transfected cells. Over-
expression of PIAS3, together with SOCS3, showed additive
inhibitory effects on cellular proliferation [Figure 3A, PIAS3
AdCATK versus PIAS3 AdSOCS3 (P = .043 on day 7)].
Growth suppression by PIAS3 was confirmed in another
Figure 2. Establishment of PIAS3-overexpressing human lung cancer cells. (A) The ectopic expression of PIAS3 was evaluated as Myc tag expression by
immunoblotting analysis with Myc-specific antibodies and was indicated as the PIAS3–cMyc fusion protein. (B) High levels of PIAS3 expression in established
clones are indicated as 68-kDa PIAS3 bands by immunoblotting. Clones stably expressing PIAS3 were established by transfecting a plasmid vector encoding
PIAS3, followed by culturing in a medium containing Geneticin. (C) Downregulation of pSTAT3 in PIAS3-overexpressing A549/PIAS3 (upper panel), LCD/PIAS3
(middle panel), and EBC1/PIAS3 (lower panel) cells. The phosphorylation of STAT3 in PIAS3-overexpressing cells was serially analyzed after IL-6 stimulation
using phosphospecific antibody.
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A549 clone [Figure 3B, A549/mock versus A549/PIAS3
clone 2 (P = .030 on day 7)]. The growth rate of PIAS3-
transfected LCD cells was also lower than that of mock-
transfected LCD cells, and representative results are shown
[Figure 3C, mock versusPIAS3 clone 1 (P = .0007 on day 6)].
Growth inhibition by PIAS3 was also observed in the other
lung cancer cell line EBC1, and the results of a representa-
tive clone are shown [Figure 3D, mock versus PIAS3 clone 1
(P = .0005 on day 6)].
We next studied the effects of PIAS3 on the sensitivity of
lung cancer cells to chemotherapeutic agents. The fold
increase in drug sensitivity was calculated as the IC50
values of mock-transfected cells divided by those of PIAS3-
transfected or SOCS-transfected cells. The sensitivities of
PIAS3-transfected A549 clones to CBDCA were from 1.9 ±
0.2–fold to 5.5 ± 2.8–fold higher (Figure 4, A549, CBDCA/
PIAS3 clones 1, 2, and 3). PIAS3-transfected LCD cells were
also 1.2-fold and 2.4-fold more sensitive to CBDCA (Figure 4,
LCD, CBDCA/PIAS3 clones 1 and 2). The relative sensitivity
of PIAS3-transfected A549 cells to VNR was from 11.0 ±
2.9 to 12.0 ± 2.6 times higher than that of mock-transfected
A549 cells (Figure 4, A549, VNR/PIAS3 clones 1, 2, and 3).
The relative sensitivity of PIAS3-transfected LCD cells to
VNR was 6.8 and 6.7 times higher than the IC50 of mock-
transfected LCD cells (Figure 4, LCD, VNR/PIAS3 clones 1
and 2). EBC1 cells transfected with PIAS3 also became
about 2.0-fold more sensitive to CBDCA and VNR, respec-
tively (Figure 4, EBC1, CBDCA/PIAS3 clone 1 and VNR/
PIAS3 clone 2). The IC50 values of SOCS3-infected A549
and LCD cells to both CBDCA and VNR were, nevertheless,
very similar to those of their respective mock-transfected
cells (Figure 4, A549, CBDCA/SOCS3, and VNR/SOCS3;
Figure 4, LCD, CBDCA/SOCS3, and VNR/SOCS3).
Overexpression of PIAS3 Suppressed Bcl-xL
and Akt Phosphorylation in Lung Cancer Cells,
Whereas Transduction of SOCS3 Did Not
It is known that the expression of Bcl-xL and Akt is
upregulated by STAT3. These molecules protect cells from
apoptosis and are associated with oncogenesis in cancer
cells [27–29]. To identify molecules mediating the anticancer
effects of PIAS3, we analyzed the activation of Bcl-xL ex-
pression, as well as the upregulation of the expression of
extracellular signal–regulated kinase (Erk) through Ras, and
of Akt through phospholipase C g and PI3-K.
In contrast to mock-transfected A549 cells, PIAS3-
transfected cells showed that both Bcl-xL expression by
CBDCA exposure (Figure 5A, PIAS3/Bcl-xL) and Akt phos-
phorylation by IL-6 stimulation were inhibited by PIAS3 over-
expression (Figure 5B, A549/PIAS3/pAkt). Erk1/2 was
similarly phosphorylated in response to IL-6 stimulation in
both mock-transfected and PIAS3-transfected A549 cells
(Figure 5B, A549/PIAS3 pErk1/2). Figure 5, A and B, pres-
ents the results obtained with A549/PIAS3 clone 1. Similar
results were also confirmed in other A549 PIAS3 clones (data
not shown). In PIAS3-overexpressing EBC1 cells, the ex-
pression of pAkt was weak before stimulation, and the en-
hanced expression of pAkt after IL-6 stimulation attenuated
sooner than that in mock-transfected EBC1 cells (Figure 5B,
EBC1/PIAS3/pAkt). Overexpression of PIAS3 in EBC1 cells
Figure 3. Overexpression of PIAS3, alone or combined with SOCS3, retarded the growth of human lung cancer cells. (A) Growth curves of the A549 transfectants
of PIAS3 (A549/PIAS3 clone 1), alone or combined with SOCS3 infection, using an adenoviral vector. Cells were infected with either AdSOCS3 or AdCATK as
control at an MOI of 20. (B) PIAS3 overexpression alone suppresses the cell growth of the other A549/PIAS3 clone (A549/PIAS3 clone 2). Effects of PIAS3
overexpression on the cell growth of LCD (C) and EBC1 (D) cells (LCD/PIAS3 clone 1 and EBC1/PIAS3 clone 1). Cells were grown in an RPMI medium containing
5% FBS. Viable cell numbers were counted using trypan blue dye exclusion at the indicated times after seeding. Each value is the average (points) of triplicate
dishes ± SD (bars).
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did not change the phosphorylation of Erk1/2 in response to
IL-6 stimulation either (Figure 5B, EBC1/PIAS3/pErk1/2).
Infection of A549 cells with AdSOCS3 caused the suppres-
sion of IL-6–stimulated STAT3 phosphorylation (Figure 5C,
AdSOCS3/pSTAT3). However, CATK-transfected and
SOCS3-transfected cells showed almost very similar levels
of Bcl-xL expression by CBDCA exposure (Figure 5C,
AdSOCS3/Bcl-xL) and phosphorylation levels of both Akt
and Erk1/2 in response to IL-6 stimulation (Figure 5C,
AdSOCS3/pAkt and AdSOCS3/pErk1/2).
Figure 4. Drug sensitivity of lung cancer cells overexpressing PIAS3 or SOCS3. The eight of bars on the left indicate the fold increase in drug sensitivity to CBDCA
and VNR in A549 cells. The six of bars on the middle of the figure indicate the fold increase in drug sensitivity in LCD cells, and the two of bars on the right indicate
the fold increase in drug sensitivity in EBC1 cells. The clones used in the PIAS3 study are indicated in each figure. Cells were transfected with AdSOCS3 or
AdCATK (mock) at an MOI of 20. The fold increase in drug sensitivity was calculated as the IC50 values of mock-transfected cells divided by those of PIAS3-
transfected or SOCS3-transfected cells. Values are expressed as mean ± SD from three individual experiments.
Figure 5. Overexpression of PIAS3 inhibits Akt phosphorylation and Bcl-xL expression in A549 cells. (A) Suppression of Bcl-xL by PIAS3 overexpression. Cells were
pretreated for 24 hours with the indicated concentrations of CBDCA. Protein extracts were probed with the Bcl-xL antibody. (B) Overexpression of PIAS3 inhibited Akt
phosphorylation but did not affect Erk1/2 phosphorylation in A549 and EBC1 cells. Exponentially growing cells in a medium containing 10% FBS were exposed to
100 ng/ml IL-6 for the indicated durations. The phosphorylation of Akt and Erk1/2 was determined using each corresponding phosphospecific antibody. (C) Effects of
SOCS3 transduction on pSTAT3, pAkt, pErk1/2, and Bcl-xL in A549 cells. Cells were exposed to 100 ng/ml IL-6 for the indicated durations. Protein extracts were
subjected to immunoblotting. The phosphorylation status of STAT3, Akt, and Erk1/2 was determined using each corresponding phosphospecific antibody. To detect
Bcl-xL expression, cells were pretreated for 24 hours with indicated concentrations of CBDCA. Protein extracts were probed with the Bcl-xL antibody.
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Blocking of PIAS3 with siRNA Accelerated Cell Proliferation
and Deteriorated Sensitivity to Chemotherapeutic Agents
in Lung Cancer Cells
To further confirm the effects of PIAS3 on the cell pro-
liferation and chemosensitivity of lung cancer cells, we sup-
pressed PIAS3 expression using siRNA. Although treatment
with a PIAS3-specific siRNA significantly suppressed PIAS3
expression, it augmented the phosphorylation of Akt in A549,
EBC1, and LCMS cells. However, the expression of total
Akt was almost similar (Figure 6A). Downregulated PIAS3
expression was associated with an accelerated growth of
both A549 and LCMS cells [Figure 6B, A549, control siRNA
versus PIAS3 siRNA (P = .0475 on day 7); Figure 6C, LCMS,
control siRNA versusPIAS3 siRNA (P = .0073 on day 7)]. The
inhibition of PIAS3 expression also resulted in the reduced
sensitivity of EBC1 and LCMS cells to CBDCA (Figure 6D).
PIAS3 Interacted with Akt In Vitro in Lung Cancer Cells
Although PIAS3 specifically binds to STAT3 [10], it is not
knownwhether PIAS3 has interactions with Akt.Weprepared
protein extracts from PIAS3-overexpressing cells stimulated
with IL-6. Proteins immunoprecipitated with Akt were sub-
jected to protein immunoblotting with anti-PIAS3. PIAS3 was
present in Akt immunoprecipitates from both A549 and EBC1
cells (Figure 7). Stimulation with IL-6 slightly enhanced the
interaction of PIAS3with Akt in both cell lines. PIAS3was also
present in Akt immunoprecipitates from wild-type A549 and
EBC1 cells (data not shown).
Discussion
The JAK/STAT pathway is activated in the cancer cell lines
used in this study (Figure 2C). Zhang et al. described that
the downregulation of PIAS3 proteins is frequently seen in
lymphoma cells and that loss of PIAS3 expression is partly
responsible for maintaining high levels of activated STAT3
Figure 6. Blocking of PIAS3 with siRNA accelerated cell proliferation, deteriorated chemosensitivity, and augmented Akt phosphorylation in lung cancer cells. (A)
Although treatment with siRNA ablated PIAS3 expression, it augmented Akt phosphorylation. Cells were transfected with siRNA specific for PIAS3 or with control
siRNA. After 48 hours of incubation, cells were harvested and protein extracts were probed with indicated antibodies. Growth acceleration of A549 (B) and LCMS
(C) cells. Cells were transfected with siRNA specific for PIAS3 or with control siRNA. Viable cell numbers were counted using trypan blue dye exclusion at the
indicated times after the transfection. Each value is the average (points) of triplicate dishes ± SD (bars). (D) Chemosensitivity of siRNA-treated EBC1 and LCMS
cells for CBDCA. The fold increase of drug sensitivity was calculated as the IC50 values of control siRNA-transfected cells divided by those of PIAS3 siRNA-
transfected cells. Values were expressed as mean ± SD from three individual experiments.
Figure 7. The in vitro interaction of PIAS3 with Akt. Protein extracts from
PIAS-overexpressing A549 and EBC1 cells, stimulated with (+) or without ()
IL-6, were immunoprecipitated (IP) with Akt. The blot was probed with anti-
PIAS3 (top). The same blot was then reprobed with anti-Akt (bottom).
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[20]. However, Wang and Banerjee [30] described that
basal amounts of PIAS3 were present in various human
cancers. In our study, immunoblotting analysis detected en-
dogenous PIAS3 proteins in A549 and LCD cells (Figure 2B).
Methylation-specific polymerase chain reaction showed
that SOCS-3 was hypermethylated in A549 and LCD cells
and, thus, the amount of transcripts of SOCS-3 was de-
creased (data not shown).
The phosphorylation of STAT3 was attenuated in PIAS3-
transfected A549 and EBC1 cells, whereas it was not changed
in PIAS3-transfected LCD cells (Figure 2C). Schmidt
and Muller discussed the mechanisms mediating the down-
regulation of the transcriptional activity of STAT by PIAS. They
presented a model in which PIAS interferes with the binding
of STAT to target DNA by covering the DNA-binding domain
of an activated STAT dimer. An alternative model is one
wherein PIAS interacts transiently with STAT dimers to induce
their dissociation and, consequently, the loss of DNA-binding
activity [31]. These models can explain the difference in the
level of expression of pSTAT3 in PIAS3-transfected A549 and
LCD cells. Therefore, PIAS proteins may act like a buffer for
maintaining the concentration of active STAT dimers within the
cell [15], and the downregulation of SOCS3 primarily accounts
for the activation of STAT3 in A549 and LCD cells.
We showed that treatment with the JAK inhibitor AG490
and the PI3-K inhibitor LY294002 contributed to the growth
suppression of lung cancer cells (Figure 1). Both PI3-K/Akt
and JAK/STAT are important regulators of cell survival and
apoptosis. Akt suppresses apoptosis by interacting with and
phosphorylating Bad, a cell survival factor [32] that in-
activates the initiation of caspase-9 [33]. Overexpression of
PIAS3 successfully downregulated the JAK/STAT pathways
(Figure 2C) and retarded the growth of these cells (Figure 3).
Themagnitude of growth suppression by SOCS3was, never-
theless, superior to that by PIAS3 (Figure 3A). Because the
methods of transfection were different between the PIAS
and SOCS genes, we speculate that the transient but strong
gene expression by adenoviruses caused more significant
inhibitory effects on cell growth.
In a previous report, overexpression of KchAP, a member
of the PIAS family in prostate cancer cells, induced apoptosis
associated with increased levels of p53 and p21 [21]. The
authors, however, did not refer to changes in drug sensitivity
or in the expression of antiapoptotic molecules such as Akt,
Bcl-xL, and Erk1/2. We demonstrated that the overexpres-
sion of PIAS3 in lung cancer cells increased drug sensitivity
(Figure 4), suppression of cell growth (Figure 3), and in-
hibition of both Akt phosphorylation in response to IL-6 and
Bcl-xL expression in exposure to CBDCA (Figure 5,A andB).
However, transduction of SOCS-3 only retarded growth
(Figure 3A) without affecting drug sensitivity or Akt phos-
phorylation (Figures 4 and 5C).
Treatment of A549 cells with LY294002 increased drug
sensitivity as well as growth suppression, but AG490
treatment did not alter the drug sensitivity of A549 cells
(Figure 1D). Roberts [34], using cDNA microarray analysis,
demonstrated a significant association of STAT1 expression
with decreased sensitivity to cisplatin in human ovarian
cancer cell lines. However, Brognard et al. [35] reported
that constitutive Akt/protein kinase B (PKB) activity was de-
tected in 16 of 17NSCLCcell lines, includingA549. ThePI3-K
inhibitors LY294002 and wortmannin inhibited Akt/PKB
phosphorylation and potentiated chemotherapy-induced
apoptosis in cancer cells. Knuefermann et al. also reported
that HER2/PI3-K–dependent activation of Akt plays an im-
portant role in conferring broad-spectrum drug resistance on
breast cancer cells. They speculate that Akt-mediated resis-
tance to chemotherapeutic agents with different mechanisms
of action is likely because of the overall antiapoptotic activity
of Akt [36]. As shown in Figures 4 Figures 5 Figures 6, we
speculate that the levels of phosphorylated Akt are regulated
byPIAS3 and are inversely correlatedwith the drug sensitivity
of lung cancer cells. Dreuw et al. [37] showed that stimulation
with IL-6 enhanced the expression of multidrug resistance–
associated proteins (MRPs) and STAT proteins. Expression
of MRPs was suppressed by the inhibition of Akt with the
PI3-K inhibitor. However, the inhibition of mitogen-activated
protein kinase/Erk1/2 did not have an inhibitory effect on the
enhanced transcription of MRP. The suppression of MRP
expression caused by Akt inactivation might account for
the increase of drug sensitivity by PIAS3. PIAS3 was pres-
ent in Akt immunoprecipitates from A549 and EBC1 cells
(Figure 7). The intensity of the bands indicating the PIAS3
proteins associated with Akt was enhanced by stimulation
with IL-6. There has been no previous report on the in-
volvement of PIAS3 in Akt activation. This result implies that
PIAS3 affects the phosphorylation of Akt, although it is
necessary to elucidate the mechanism.
In conclusion, using PIAS3 in targeting the JAK/STAT
signaling pathways against cancer has the advantages of
restoring sensitivity to chemotherapeutic drugs and inhibiting
cell growth.
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